Discovery of new riminophenazine analogues as antimycobacterial agents against drug-resistant Mycobacterium tuberculosis. 2022

Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Twenty-three new riminophenazine and pyrido[3,2-b]quinoxaline derivatives were prepared and examined for their antimycobacterial activities against Mycobacterium marinum and Mycobacterium tuberculosis H37Rv, taking clofazimine (1) as the lead. Structure-activity relationship (SAR) analysis revealed that the introduction of a heterocycle or diethylamine substituted benzene moiety on the N-5 atom might be beneficial for activity. The most potent compound 7m also displayed enhanced activity against wild-type as well as multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB clinical isolates, with the MICs ranging from 0.08 to 1.25 μg/mL, especially effective toward strain M20A507, resistant to 1. Further mechanism study indicated that its anti-TB activity was independent of cell membrane disruption, but related to NDH-2 reduction and the resulting high ROS production. Our study provides instructive guidance for the further development of clofazimine derivatives into promising antimicrobial agents against MDR and XDR TB.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002991 Clofazimine A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) B-663,G-30,320,Lamprene,N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine,B 663,B663,G 30,320,G30,320
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
April 2018, European journal of medicinal chemistry,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
November 2021, Bioorganic & medicinal chemistry,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
September 2017, Trends in microbiology,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
January 2021, Colloids and surfaces. B, Biointerfaces,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
April 2017, mBio,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
June 2017, MedChemComm,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
May 2024, Scientific reports,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
April 2005, Bioorganic & medicinal chemistry letters,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
July 2016, Advanced drug delivery reviews,
Xiaoqiang Zhao, and Yuheng Mei, and Zhihao Guo, and Shuyi Si, and Xican Ma, and Yinghong Li, and Yan Li, and Danqing Song
June 2015, International journal of antimicrobial agents,
Copied contents to your clipboard!